Linked Color Imaging Focused on Neoplasm Detection in the Upper Gastrointestinal Tract : A Randomized Trial.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 21 10 2020
medline: 10 2 2021
entrez: 20 10 2020
Statut: ppublish

Résumé

Linked color imaging (LCI) is a new image-enhanced endoscopy technique that allows users to recognize slight differences in mucosal color. To compare the performance of LCI with white light imaging (WLI) in detecting neoplastic lesions in the upper gastrointestinal tract. A controlled, multicenter trial with randomization using minimization. (University Hospital Medical Information Network Clinical Trials Registry: UMIN000023863). 16 university hospitals and 3 tertiary care hospitals in Japan. 1502 patients with known previous or current cancer of the gastrointestinal tract and undergoing surveillance for gastrointestinal cancer. WLI followed by LCI examination (WLI group) or LCI followed by WLI examination (LCI group). Diagnosis of 1 or more neoplastic lesions in the pharynx, esophagus, or stomach in the first examination (primary outcome) and 1 or more neoplastic lesions overlooked in the first examination (secondary outcome). 752 patients were assigned to the WLI group and 750 to the LCI group. The percentage of patients with 1 or more neoplastic lesions diagnosed in the first examination was higher with LCI than with WLI (60 of 750 patients or 8.0% [95% CI, 6.2% to 10.2%] vs. 36 of 752 patients or 4.8% [CI, 3.4% to 6.6%]; risk ratio, 1.67 [CI, 1.12 to 2.50; Endoscopists were not blinded. LCI is more effective than WLI for detecting neoplastic lesions in the pharynx, esophagus, and stomach. Fujifilm Corporation.

Sections du résumé

BACKGROUND
Linked color imaging (LCI) is a new image-enhanced endoscopy technique that allows users to recognize slight differences in mucosal color.
OBJECTIVE
To compare the performance of LCI with white light imaging (WLI) in detecting neoplastic lesions in the upper gastrointestinal tract.
DESIGN
A controlled, multicenter trial with randomization using minimization. (University Hospital Medical Information Network Clinical Trials Registry: UMIN000023863).
SETTING
16 university hospitals and 3 tertiary care hospitals in Japan.
PATIENTS
1502 patients with known previous or current cancer of the gastrointestinal tract and undergoing surveillance for gastrointestinal cancer.
INTERVENTION
WLI followed by LCI examination (WLI group) or LCI followed by WLI examination (LCI group).
MEASUREMENTS
Diagnosis of 1 or more neoplastic lesions in the pharynx, esophagus, or stomach in the first examination (primary outcome) and 1 or more neoplastic lesions overlooked in the first examination (secondary outcome).
RESULTS
752 patients were assigned to the WLI group and 750 to the LCI group. The percentage of patients with 1 or more neoplastic lesions diagnosed in the first examination was higher with LCI than with WLI (60 of 750 patients or 8.0% [95% CI, 6.2% to 10.2%] vs. 36 of 752 patients or 4.8% [CI, 3.4% to 6.6%]; risk ratio, 1.67 [CI, 1.12 to 2.50;
LIMITATION
Endoscopists were not blinded.
CONCLUSION
LCI is more effective than WLI for detecting neoplastic lesions in the pharynx, esophagus, and stomach.
PRIMARY FUNDING SOURCE
Fujifilm Corporation.

Identifiants

pubmed: 33076693
doi: 10.7326/M19-2561
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18-24

Investigateurs

Yuichi Shimizu (Y)
Satoshi Abiko (S)
Keiko Yamamoto (K)
Takahiko Kudo (T)
Kana Matsuda (K)
Kazuhiro Kamada (K)
Takahiro Nakano (T)
Kei Terasaki (K)
Shun Takayama (S)
Kazayuki Ogita (K)
Yasuaki Nakajima (Y)
Tetsuji Takayama (T)
Hironori Wada (H)
Masanori Takehara (M)
Kaizou Kagemoto (K)
Fumika Nakamura (F)
Atsushi Masamune (A)
Waku Hatta (W)
Hiroyuki Okada (H)
Masaya Iwamuro (M)
Makoto Abe (M)
Tatsuhiro Gotoda (T)
Hiroyuki Sakae (H)
Akiko Shiotani (A)
Hiroshi Matsumoto (H)
Minoru Fujita (M)
Motoyasu Oosawa (M)
Tatsushi Omatsu (T)
Takeshi Yasuda (T)
Akio Ido (A)
Hidehito Maeda (H)
Masayuki Kabayama (M)
Ken Ohnita (K)
Kazuhiko Nakao (K)
Shinji Tanaka (S)
Takahiro Kotachi (T)
Akifumi Fukui (A)
Akito Harusato (A)
Kouhei Oka (K)
Takashi Akutagawa (T)
Kazunari Murakami (K)
Ryo Ogawa (R)
Hirofumi Kawamoto (H)
Ken Haruma (K)
Kazuhide Higuchi (K)
Yuichi Kojima (Y)
Kazuhiro Ota (K)
Katsuhiro Mabe (K)
Kimitoshi Kubo (K)

Auteurs

Shoko Ono (S)

Hokkaido University Hospital, Sapporo, Japan (S.O., M.T.).

Kenro Kawada (K)

Tokyo Medical and Dental University, Tokyo, Japan (K.K.).

Osamu Dohi (O)

Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan (O.D., Y.N.).

Shinji Kitamura (S)

Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan (S.K.).

Tomoyuki Koike (T)

Tohoku University Graduate School of Medicine, Sendai, Japan (T.K.).

Shinichiro Hori (S)

National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan (S.H.).

Hiromitsu Kanzaki (H)

Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan (H.K.).

Takahisa Murao (T)

Kawasaki Medical School, Okayama, Japan (T.M.).

Nobuaki Yagi (N)

Asahi University Hospital, Gifu, Japan (N.Y.).

Fumisato Sasaki (F)

Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan (F.S.).

Keiichi Hashiguchi (K)

Nagasaki University Hospital, Nagasaki, Japan (K.H.).

Shiro Oka (S)

Hiroshima University Hospital, Hiroshima, Japan (S.O.).

Kazuhiro Katada (K)

North Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan (K.K.).

Ryo Shimoda (R)

Saga University, Saga, Japan (R.S.).

Kazuhiro Mizukami (K)

Oita University, Oita, Japan (K.M.).

Mitsuhiko Suehiro (M)

Kawasaki Medical School General Medical Center, Okayama, Japan (M.S., K.H.).

Toshihisa Takeuchi (T)

Osaka Medical College, Osaka, Japan (T.T.).

Shinichi Katsuki (S)

Otaru Ekisaikai Hospital, Otaru, Japan (S.K.).

Momoko Tsuda (M)

Hokkaido University Hospital, Sapporo, Japan (S.O., M.T.).

Yuji Naito (Y)

Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan (O.D., Y.N.).

Tatsuyuki Kawano (T)

Soka Municipal Hospital, Soka, Japan (T.K.).

Ken Haruma (K)

Kawasaki Medical School General Medical Center, Okayama, Japan (M.S., K.H.).

Hideki Ishikawa (H)

Kyoto Prefectural University of Medicine, Osaka, Japan (H.I.).

Keita Mori (K)

Shizuoka Cancer Center, Shizuoka, Japan (K.M.).

Mototsugu Kato (M)

National Hospital Organization Hakodate National Hospital, Hakodate, Japan (M.K.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH